A prospective real-world analysis of erenumab in refractory chronic migraine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Clinical trials have shown the safety and clinical superiority of erenumab compared to placebo in chronic migraine (CM). The aim of this analysis is to evaluate the effectiveness and tolerability of erenumab in a real-world setting in patients with refractory CM. Methods: This is a prospective single centre real-world audit conducted in patients with CM with and without medication overuse, refractory to established preventive medications, who received monthly erenumab for 6 months. Results: Of 164 patients treated, 162 patients (female = 135, mean age 46 ± 14.3 years old) were included in the audit. Patients had failed a mean of 8.4 preventive treatments at baseline and 91% of patients failed Botulinum toxin type A at baseline. The mean reduction in monthly migraine days was 6.0 days at month 3 (P = 0.002) and 7.5 days at month 6 (P < 0.001) compared to baseline. The mean reduction in monthly headache days was 6.3 days (P < 0.001) at month 3 and 6.8 days (P < 0.001) at month 6. At month 3, 49%, 35% and 13% and at month 6, 60%, 38% and 22% of patients obtained at least a 30%, 50% and 75% reduction in migraine days, respectively. The percentage of patients with medication overuse was reduced from 54% at baseline to 20% at month 3 and to 25% at month 6. Compared to baseline, the mean reduction of Headache Impact Test-6 score was 7.7 points at month 3 (from 67.6 ± 0.4 to 59.9 ± 0.9) (P < 0.001) and of 7.5 points at month 6 (60.1 ± 1.3) (P = 0.01). The percentage of patients with severe headache-related disability (HIT-6: 60–78) was reduced from 96% at baseline to 68% after three monthly treatments and to 59% after six treatments. At least one side effect was reported by 48% of patients at month 1, 22% at month 3 and 15% at month 6. Constipation (20%) and cold/flu-like symptoms (15%) were the most frequent adverse events reported. Conclusion: Erenumab may be an effective and well tolerated therapy for medically refractory CM patients with and without medication overuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337 · cited 1×
“The combination of daily or nearly daily head pain, other comorbidities, namely psychiatric, sleep and pain related, along with the frequent association with medication overuse headache (MOH), contributes to the high degree of socioeconomic burden typical of this condition [3].”
BackgroundDworkin, R. H., Turk, D. C., McDermott, M. P., Peirce-Sandner, S., Burke, L. B., Cowan, P., Farrar, J. T., Hertz, S., Raja, S. N., Rappaport, B. A., et al. (2009) · Pain · doi:10.1016/j.pain.2009.08.019 · Cited by 654
Bloudek, L. M., Stokes, M., Buse, D. C., Wilcox, T. K., Lipton, R. B., Goadsby, P. J., Varon, S. F., Blumenfeld, A. M., Katsarava, Z., Pascual, J., et al. (2012) · The Journal of Headache and Pain · doi:10.1007/s10194-012-0460-7 · Cited by 339
Chronic Migraine: Epidemiology and Disease Burden
Manack, A. N., Buse, D. C., & Lipton, R. B. (2011) · Current Pain and Headache Reports · doi:10.1007/s11916-010-0157-z · Cited by 230
Cited by
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
Migraine: integrated approaches to clinical management and emerging treatments
Ashina, M., Buse, D. C., Ashina, H., Pozo-Rosich, P., Peres, M. F. P., Lee, M. J., Terwindt, G. M., Halker Singh, R., Tassorelli, C., Do, T. P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32342-4 · Cited by 305
Lloyd, J. O., Hill, B., Murphy, M., Al-Kaisy, A., Andreou, A. P., & Lambru, G. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01428-6 · Cited by 21
“Erenumab has been recently shown to be a potentially effective treatment in refractory CM, though long-term data are missing [8].”
BackgroundSelf-citationApplications of transcranial magnetic stimulation in migraine: Evidence from a scoping review
Calabrò, R. S., Billeri, L., Manuli, A., Iacono, A., & Naro, A. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2104110 · Cited by 9
Metadata
- Authors
- Lambru, G., Hill, B., Murphy, M., Tylova, I., & Andreou, A. P.
- Venue
- The Journal of Headache and Pain
- Published
- 2020-06-01
- Volume
- 21
- Issue
- 1
- Pages
- 61-61
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- OpenAlex
- W3030140473
- Cited by
- 182
- References
- 4
- FWCI
- 21.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A prospective real-world analysis of erenumab in refractory chronic migraine. https://app.cochat.ai/papers/10.1186/s10194-020-01127-0
- The paper
- Lambru, G., Hill, B., Murphy, M., Tylova, I., & Andreou, A. P. (2020). A prospective real-world analysis of erenumab in refractory chronic migraine. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-020-01127-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.